Skip to main content

Drug Interactions between Rapiblyk and trandolapril

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

trandolapril landiolol

Applies to: trandolapril and Rapiblyk (landiolol)

GENERALLY AVOID: Concomitant use of landiolol with negative inotropes, medications that slow heart rate or cardiac conduction should be done with caution. Coadministration may result in additive suppression of cardiac function, atrioventricular (AV) conduction abnormalities, prolonged PR interval, and potentially additive heart-rate and blood pressure lowering effects. Landiolol alone is associated with increased risk of bradycardia and heart block, and therefore coadministration with these agents may potentiate these effects.

MANAGEMENT: If coadministration is clinically necessary, careful titration of the landiolol infusion and close hemodynamic monitoring is advised. Consultation with package labeling and relevant institutional protocols may be advisable for further guidance.

References (2)
  1. (2024) "Product Information. Sibboran (landiolol)." Trimedic Therapeutics Inc.
  2. (2024) "Product Information. Rapiblyk (landiolol)." AOP Orphan Pharmaceuticals GmbH

Drug and food interactions

Moderate

trandolapril food

Applies to: trandolapril

GENERALLY AVOID: Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors. In some cases, affected patients were using a potassium-rich salt substitute. ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.

MANAGEMENT: It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake. Particular attention should be paid to the potassium content of salt substitutes.

References (3)
  1. (2002) "Product Information. Vasotec (enalapril)." Merck & Co., Inc
  2. Good CB, McDermott L (1995) "Diet and serum potassium in patients on ACE inhibitors." JAMA, 274, p. 538
  3. Ray K, Dorman S, Watson R (1999) "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens, 13, p. 717-20

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer